PhalconBio Receives €250,000 to Advance Inhaled Dual-Action Phages Against Pseudomonas Pneumonia
Swiss biotechnology company PhalconBio has received €250,000 in Stage II funding from the Incubator for Antimicrobial Therapies in Europe, or INCATE, to advance an inhaled bacteriophage therapy targeting severe ventilator-associated pneumonia caused by Pseudomonas aeruginosa. The programme combines conventional phage-mediated bacterial killing with an additional antibacterial mechanism encoded within the therapeutic phage, an approach the company calls Dual-Action Phages.
The award represents a translational step for PhalconBio's lead pulmonary programme. INCATE's funding will support production of the candidate therapy and preclinical work intended to generate evidence relevant to future pharmaceutical development. The programme is being developed as a complement to standard-of-care antibiotics rather than as an immediate replacement for them, with inhaled administration intended to deliver the therapeutic phages directly to the infected respiratory tract.
Ventilator-associated pneumonia remains a major problem in intensive care units because it develops in patients already requiring mechanical ventilation and can be particularly difficult to treat when caused by multidrug-resistant Gram-negative bacteria. P. aeruginosa is a prominent concern because of its intrinsic and acquired antibiotic resistance mechanisms, its capacity to form biofilms and its ability to persist in damaged or heavily treated respiratory environments.
For phage therapy, pulmonary infection also presents a compelling route of administration. Instead of relying entirely on systemic delivery, inhalation can potentially expose bacteria in the airways and lungs directly to the therapeutic preparation. This does not eliminate challenges involving phage stability, mucus, immune clearance, bacterial heterogeneity or delivery within biofilms, but it provides a logical strategy for maximizing local exposure while combining phages with existing antimicrobial treatment.
PhalconBio's programme differs from a conventional therapeutic phage approach because its Dual-Action Phages are designed to provide two antibacterial effects. The first is the natural ability of a lytic bacteriophage to infect a susceptible bacterial cell, replicate and ultimately destroy it. The second is an additional antibacterial activity encoded by the phage genome and delivered during infection.
According to PhalconBio, infected bacteria are effectively used to produce antibacterial proteins encoded by the engineered phage. The pathogen therefore becomes part of the production system for a second antibacterial mechanism at the infection site, while phage replication simultaneously drives the conventional viral infection cycle. The company is developing this strategy with the aim of strengthening bacterial killing and reducing opportunities for resistant bacteria to escape treatment while maintaining the strain-level precision associated with bacteriophages.
The €250,000 award will notably support a planned randomized study in a mechanically ventilated porcine model of P. aeruginosa ventilator-associated pneumonia. PhalconBio states that the model has been developed by the group of Prof. Antoni Torres and Dr. Laia Fernández-Barat at FRCB-IDIBAPS and Hospital Clínic Barcelona.
The study is expected to compare standard-of-care antibiotics alone with antibiotics combined with inhaled Dual-Action Phages. Investigators will examine antibacterial efficacy as well as pulmonary delivery and tolerability under experimental conditions intended to reproduce important aspects of mechanically ventilated intensive-care patients.
This is an important distinction in understanding the current stage of the programme. The INCATE award does not represent the beginning of a human clinical trial, and the candidate remains in preclinical development. The planned animal study is instead intended to bridge the gap between demonstrating antibacterial activity in relatively simplified systems and testing the therapy under conditions that more closely reproduce severe respiratory disease, mechanical ventilation and clinically relevant delivery constraints.
For inhaled phage therapies, establishing biological activity in the lung is only one part of development. Developers must also determine whether sufficient viable phage reaches the target site, whether administration is reproducible, whether the preparation remains stable during delivery and how the treatment behaves when administered alongside antibiotics. A ventilated large-animal model can therefore provide information that cannot easily be obtained from standard bacterial cultures or smaller experimental systems.
PhalconBio co-founder and General Manager Samuel Kilcher described the Stage II award as a transition from demonstrating the potential of the company's technology toward producing the evidence required to advance a pharmaceutical candidate. The broader objective is to build a preclinical package capable of supporting licensing discussions and eventual clinical development if the programme continues to produce favourable results.
The funding also places the project within a broader European effort to accelerate technologies targeting antimicrobial resistance. INCATE was established to support early-stage ventures developing antimicrobial therapies and interventions that may otherwise struggle to cross the gap between academic innovation and commercial drug development. Its partners include the German Center for Infection Research, the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute, NCCR AntiResist and the University of Basel, together with pharmaceutical and translational partners.
PhalconBio is the sixth company to receive INCATE Stage II support. The German Center for Infection Research reports that INCATE has awarded more than €2 million since its launch in 2021 to support early-stage antimicrobial-resistance ventures. The programme provides not only financing but also company-building and translational support intended to move promising technologies toward development milestones attractive to pharmaceutical partners and investors.
PhalconBio's programme has also previously received external support. The company reports that PACE awarded £1 million to advance its anti-Pseudomonas programme, providing additional resources for development before the new INCATE Stage II award. Together, these funding rounds indicate that the programme is moving from platform development toward the generation of indication-specific preclinical evidence.
The lead indication is currently ventilator-associated pneumonia, but PhalconBio presents Dual-Action Phages as a broader antibacterial platform rather than a single-product technology. The company has identified burn wound infections as another potential application and states that different combinations of phages and antibacterial proteins could be developed against additional pathogens and clinical indications.
Artificial intelligence-assisted protein design is also being incorporated into the platform. Rather than modifying only the bacteriophage itself, the concept allows PhalconBio to potentially optimize the additional antibacterial payload carried by the virus. This creates a modular development strategy in which both phage specificity and the encoded antibacterial mechanism could be adjusted according to the targeted pathogen or therapeutic objective.
The company is collaborating with several academic and clinical institutions, including ETH Zurich, the University of Basel, Institut Pasteur, Loughborough University and the Barcelona clinical research group associated with the planned pulmonary study. Such partnerships are particularly relevant for engineered phage development because the technology sits at the intersection of phage biology, protein engineering, manufacturing, respiratory medicine and regulatory science.
The Dual-Action Phage concept also reflects a broader evolution taking place across the phage-therapy field. Classical personalized phage therapy generally relies on identifying naturally occurring phages that can kill a patient's bacterial isolate. Newer platforms increasingly attempt to engineer additional properties into those viruses, ranging from altered host specificity to delivery of functional biological payloads.
That additional complexity could create advantages but also raises the development bar. Engineered phages must still demonstrate adequate host specificity, manufacturing consistency, genetic stability and safety, while their added biological functions need to be characterized independently from conventional phage replication. For inhaled products, formulation and delivery become further variables that must remain compatible with a viable and biologically active virus.
The planned porcine study will therefore provide more than a simple test of whether the phages can reduce P. aeruginosa levels. If successful, it could provide evidence on whether the Dual-Action concept remains functional when administered through the respiratory route under conditions approximating severe ventilator-associated pneumonia and when combined with antibiotics.
Resistance will also be an important question. Phage resistance can emerge rapidly through modification or loss of bacterial receptors, changes in surface structures and activation of intracellular antiviral systems. PhalconBio's rationale is that combining phage infection with a second antibacterial mechanism may make escape more difficult than resistance to a single mode of action, although the extent to which this translates into improved resistance control will need to be demonstrated experimentally.
The programme is consequently positioned at an interesting intersection between personalized bacteriophage biology and engineered antimicrobial platforms. Instead of treating a phage purely as a self-replicating antibacterial agent, the Dual-Action approach uses it simultaneously as a pathogen-specific virus and as a delivery vehicle for an additional antibacterial function.
For the wider phage-therapy field, the importance of the INCATE award lies less in its €250,000 value alone than in what the funding is intended to support. PhalconBio is moving toward a randomized large-animal respiratory study designed around clinically relevant delivery, antibiotic combination therapy and severe P. aeruginosa pneumonia. Generating convincing data at this stage will be necessary before the programme can progress toward human development.
If the approach demonstrates reproducible pulmonary delivery, tolerability and improved antibacterial activity compared with antibiotics alone, it would provide important support for further development of engineered phages as inhaled precision antibacterials. The programme nevertheless remains preclinical, and the upcoming work will need to establish whether the technological advantages proposed for Dual-Action Phages translate into meaningful benefits under conditions that increasingly resemble the patients they are ultimately intended to treat.
Sources :
German Center for Infection Research (DZIF) — INCATE awards PhalconBio Stage II Funding to advance Dual-Action Phages for severe bacterial pneumonia
https://www.dzif.de/en/incate-awards-phalconbio-stage-ii-funding-advance-dual-action-phages-severe-bacterial-pneumonia
INCATE — INCATE awards PhalconBio Stage II Funding to advance Dual-Action Phages for severe bacterial pneumonia
https://www.incate.net/incate-awards-phalconbio-stage-ii-funding/
PhalconBio — PhalconBio Receives INCATE Stage II Award
https://www.phalconbio.com/news/phalconbio-receives-incate-stage-ii-award
.png){kind=logo}
Comments
Post a Comment